Skip to main content
Premium Trial:

Request an Annual Quote

DNAlytics, VIB Partner to Develop Colorectal Cancer Screening Test

NEW YORK (GenomeWeb) – DNAlytics and Belgian life sciences research institute VIB announced today that they have formed a collaboration to develop a blood-based screening test for colorectal cancer.

According to the partners, the test will be based on the work of VIB-KU Leuven's Massimiliano Mazzone and his colleagues, who identified a 23-gene expression signature in tumor-educated circulating monocytes that can be used for colorectal cancer diagnosis. The signature has been evaluated in blood samples from about 550 individuals — both healthy volunteers and colorectal cancer patients — and has demonstrated sensitivity and specificity of over 90 percent, they added. Additional clinical validation is ongoing.

DNAlytics will use this signature with an online software platform that combines transcriptomic inputs with machine learning to develop a colorectal cancer screen — to be called ColonoKit — that it expects will be used prior to colonoscopy.

Additional terms of the deal were not disclosed.

"With this test we strike several birds with one blow," DNAlytics CEO Thibault Helleputte said in a statement. "It has a higher performance than the current available tests, and since it is a blood test it might lower the reluctance seen in patients towards the stool test."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.